US FDA declines to approve Aldeyra's drug for eye disorder
17/03/2026 12:33
March 17 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' ALDX.O drug for a type of eye disease, the company said. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sherry Jacob-Phillips) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Bausch + Lomb
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser